Chapter 5

What the Price Expects

By the close on July 27, 2026, Allegion traded at $158.14, a market value of $13.69 billion and — with $1.62 billion of net debt — an enterprise value near $15.3 billion. That price is the last line of the story the earlier chapters told: a business that earns the richest margins in its comparison set (The richest corner), defends them by being written into building specifications (Written into the Wall), converts more than all its earnings to cash and is now redirecting that cash into bought international growth (Where the Cash Goes), run by a team whose word has mostly been good (Track Record). This chapter turns that record into arithmetic: what growth, margin and cash-conversion path a buyer at $158 is underwriting, how far sentiment moved to get here, and which of the tensions the earlier acts raised are the ones the valuation actually rests on.

The multiple, as arithmetic

Sources: price and share count as reported; forward multiples derived from consensus estimates; trailing free cash flow of $685.7M from the FY2025 cash flow statement [5].

Trailing free cash flow of $685.7 million against the $13.69 billion market value is a 5.0% yield — roughly 20 times cash flow [5]. On earnings, the price is about 17.7 times consensus FY2026 EPS of $8.94, 16.3 times FY2027's $9.72, and 14.8 times FY2028's $10.68 — a multiple that steps down each year only because the earnings line is modeled to keep climbing. On the trailing year the same price is roughly 19 times FY2025 adjusted EPS of $8.14, or 21 times the $7.44 the company actually reported under GAAP. The dividend adds about 1.3%: $175.3 million paid last year, lifted to a $0.55 quarterly rate, a steady but minor part of the return.

None of those numbers is high or low on its own. What makes them a premium is the company they keep.

A premium built on margins

Source: FY2025 peer comparison, derived from reported financials; prices as reported.

Allegion's 5.0% free-cash-flow yield sits about 87 basis points below the 5.9% peer median — a richer multiple than the median name in the set. What the reader is paying up for is visible one column to the left: a 21.1% operating margin and a 16.9% free-cash-flow margin, both the highest in the group and roughly double the medians. The premium is a margin premium, priced against exactly the durability question raised in Written into the Wall — whether the specification moat that produces those margins holds as the fastest-growing, most contested electronic products grow into the mix.

Source: FY2025 peer comparison, derived from reported financials; prices as reported.

The one peer whose margin rivals Allegion's — Honeywell, at 21.7% — trades richer still, on a 3.4% free-cash-flow yield, so the market is not treating high margins as a reason to discount. The cheaper names in the set carry the lower margins: Spectrum Brands yields 7.2% on a 4.4% operating margin. The scatter reads as a fair-value line the market has drawn between quality and yield, with Allegion priced on it rather than off it. That is the calm reading. The tape over the last six months was anything but calm.

A round trip the headline hides

The facts table shows Allegion 12.0% below its high, close to the 10.9% peer median — a mild-looking number. It hides a full round trip. Inside the same window the stock peaked at $179.77 on February 6, fell to $125.65 by May 15 — a 30.1% peak-to-trough decline — then rebounded 25.9% to $158.

Source: daily closing prices, as reported (Jan 28 – Jul 27, 2026).

Each leg is dated to an earnings print, not to macro drift. The stock fell 9.4% on February 17, when the Q4 FY2025 result missed on both lines (revenue 0.4% light, EPS 2.0% short) and the company set an initial 2026 guide the market read as cautious. It fell another 7.1% on April 28, when Q1 FY2026 EPS missed by 5.1% on the self-inflicted international ERP stumble described in Track Record. Then on July 23 it jumped 10.5% — on roughly four times normal volume — when Q2 FY2026 beat revenue by 2.8% and EPS by 8.3%, and management raised the full-year adjusted-EPS outlook to $8.85–$9.00 with organic growth lifted to 3.5%–4.5% [1].

Source: daily price moves and consensus beat/miss, as reported.

Two features matter for reading the price today. First, expectations were reset down about 30% and re-elevated to near the prior level in six months, so the mild headline drawdown understates how much the market's mind changed. Second, the entire recovery rests on two consecutive revenue beats and one large EPS beat: the stock is priced as if the Q2 momentum is the trend, and management's own framing on the July call — that specification activity is pointing to "positive momentum for non-residential projects over the next 12 to 18 months" — is doing work in that price [4]. One honest limit: the price series available here runs only from late January 2026, so the "high" this drawdown is measured against is that February peak, not a verified multi-year high; a longer lookback could show a deeper decline.

What consensus is underwriting

Behind the multiple is a specific forecast. Consensus has revenue growing 8.5% in FY2026 — faster than FY2025's actual 7.8%, and against a peer median that shrank 2.3% — then decelerating to about 5% a year through FY2028 ($4.41bn, $4.63bn, $4.86bn). Normalized EPS is modeled to compound roughly 9%–10%, ahead of revenue, which means the forecast bakes in both continued margin expansion and the drip of buybacks. That EPS pace sits just below the "double-digit adjusted-EPS growth over the cycle" standard management set at its 2025 Investor Day, noted in Track Record — so consensus is underwriting management's framework at a modest discount, not a premium.

Source: FY2025 as reported; FY2026E–FY2028E consensus estimates.

The more revealing detail is what is supposed to drive that top line. Broker models show a handoff: the pricing that carried revenue through the inflation years fades — from about 3.1 points of growth in FY2026 to 1.3 by FY2028 — while volume is modeled to more than double its contribution, and the acquisition contribution that added 3.3 points rolls to essentially zero. Organic growth holds near 4.4% only if that volume rebound actually arrives.

Source: broker models, consensus estimates; growth-bridge contributions in percentage points.

That handoff is the quality question the earlier chapters left open, now in the numbers. The pricing that is fading is the cost-recovery pricing described in Written into the Wall; the acquisitions rolling to zero are the accelerating program in Where the Cash Goes, which the models simply stop crediting rather than extrapolate. And the international recovery the model needs — organic growth swinging from −1.2% in FY2026 to +3.6% in FY2027 — sits in the exact segment holding the company's only recent execution failure. On the July call management confirmed international was still down 1.2% organically on German weakness, recovered sequentially from the ERP disruption, and layered in about $10 million of annual restructuring savings [3].

One tension deserves a plain statement. Consensus pays up for 8.5% revenue growth, yet models near-flat free cash flow — an implied FY2026 figure around $690 million against $685.7 million trailing, and a forward free-cash-flow yield still at 5.0%. The growth the price is buying does not, on these estimates, translate into more free cash flow per share next year. And the forecast thins as it lengthens: FY2027 EPS spans $9.29 to $10.35 across 11 analysts, FY2028 draws only five, and every FY2029 figure rests on a single estimate — so the outer-year compounding embedded in the multiple is a small-panel view, not a firm consensus.

The questions the price hangs on

The valuation is most sensitive to four questions the earlier chapters raised and could not close. None is a verdict; each is a shared fact with a live disagreement and a specific thing that would settle it.

Sources: FY2025 peer comparison and segment disclosures, derived from reported financials; broker models and consensus estimates; Q2 FY2026 earnings call [3].

The watch items follow directly, each a line a reader can check in a future release. Americas organic volume is the single most load-bearing input: the price→volume handoff needs volume to accelerate toward mid-single digits, and the next test is the Q3 FY2026 print. International organic growth, guided to a low-single-digit decline for the full year, needs to turn positive; the German restructuring is scheduled to reach its full $10 million run-rate by the fourth quarter [1]. Free cash flow per share is the reconciler: consensus has it roughly flat, so any acceleration or slippage in available cash flow — year-to-date it was $260.8 million — moves the yield the premium rests on. And the acquisition cadence and leverage — net debt at 1.6 times adjusted EBITDA — will show whether the accelerating program the model ignores is adding value or simply lowering the blended margin.

There is one more tell worth holding. On the July call, with the stock still well below its February high, management said it saw "attractive valuation in our shares" — yet its own outlook deliberately excludes any incremental buyback [2]. Said and did point in the direction the capital chapter already drew: the cash that could shrink the share count is being kept in reserve for deals. A buyer at $158 is paying a margin-based premium for the richest corner of a fragmented industry, and underwriting a forecast in which fading price gives way to a volume rebound, a bought international segment recovers on schedule, and an acquisition program the models decline to credit either earns its keep or gets out of the way. The record says the incumbent team has met more of its commitments than it has missed. The open commitments — all dated, all checkable — sit in the parts of the business the market has seen least.